The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products.
Under the terms of the non-exclusive agreement, Prometheus will receive an upfront payment for the development of the first diagnostic array, additional payments for the development of each additional array, and research and development support and testing fees.
"This program represents an important addition to the expanding list of collaborations using our proprietary CEER diagnostic platform," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "We believe our technology can increase the probability of success in clinical trials and constitutes a significant step towards personalized medicine in cancer treatment, with the ultimate goal of improving the potential outcome for patients."
Prometheus' proprietary oncology diagnostic platform has the ability to measure the expression and activation of specific cancer pathways with high levels of sensitivity and specificity via tissue or blood sample. This technology has the potential to be used not only in the development process to select and evaluate the efficacy of drugs but also in the clinical setting to enable real-time molecular profiling, monitor drug effectiveness and direct the use of a growing number of targeted therapies.